Benzinga | Oct 20, 2021 07:14AM EDT

BeiGene And Nanolek Announce Approval In Russia For BRUKINSA For Treatment Of Patients With Relapsed Or Refractory Mantle Cell Lymphoma

This marks the first regulatory approval for BRUKINSA in Russia

BRUKINSA is now approved for the treatment of MCL in ten countries, following the U.S., China, Canada, Australia, and others

BeiGene is committed to rapidly advancing the global registration of BRUKINSA on its own and alongside strategic collaborators

Under an exclusive distribution agreement, Nanolek will commercialize BRUKINSA in Russia